Suppr超能文献

采用锝-99m二乙三胺五乙酸气雾剂(99mTc-DTPA)闪烁显像法检测接受含博来霉素化疗患者的肺上皮通透性。

Pulmonary epithelial permeability in patients treated with bleomycin containing chemotherapy detected by technetium-99m diethylene triamine penta-acetic acid aerosol (99mTc-DTPA) scintigraphy.

作者信息

de Azambuja Evandro, Fleck James Freitas, Barreto Sérgio Saldanha Menna, Cunha Rentato Duarte

机构信息

Department of Clinical Oncology, Hospital de Clínicas de Porto Alegre, Universidade Federal do Rio Grande do Sul, Porto Alegre, RS, Brazil.

出版信息

Ann Nucl Med. 2005 Apr;19(2):131-5. doi: 10.1007/BF03027392.

Abstract

PURPOSE

To evaluate pulmonary epithelial permeability using 99mTc-DTPA scintigraphy in patients treated with bleomycin-containing regimens.

MATERIAL AND METHODS

Twelve non-smoking chemotherapy-naïve patients with no clinical or radiological evidence of pulmonary disease and treated with bleomycin-containing chemotherapy were tested with 99mTc-DTPA scintigraphy before the first cycle and every 3 weeks until the third month after the end of chemotherapy (total cumulative dose of bleomycin 347.9 mg).

RESULTS

Pretreatment values (T1/2 74.93 minutes) of 99mTc-DTPA scintigraphy were significantly higher than those obtained after the total dose of bleomycin (T1/2 51.00 minutes) (p < 0.001). This difference was more important in the later evaluations especially, on the third week and third month measures after discontinuing treatment (p < 0.001). All the tests of Within-Subjects Effects were significant (p < 0.001). Comparing pretreatment and post-treatment scintigraphies the mean T1/2 99mTc-DTPA values decreased as the bleomycin dose increased.

CONCLUSION

We conclude that cumulative bleomycin doses are related to increased pulmonary epithelial permeability at a dose of 256.5 mg. However, whether this is related to clinical toxicity is uncertain and large, multi-center prospective studies are needed.

摘要

目的

使用99mTc-DTPA闪烁扫描术评估接受含博来霉素方案治疗的患者的肺上皮通透性。

材料与方法

12名未吸烟且未接受过化疗、无肺部疾病临床或影像学证据、接受含博来霉素化疗的患者,在第一个周期前以及化疗结束后直至第三个月期间,每3周进行一次99mTc-DTPA闪烁扫描术检测(博来霉素总累积剂量为347.9毫克)。

结果

99mTc-DTPA闪烁扫描术的预处理值(T1/2为74.93分钟)显著高于博来霉素总剂量后的检测值(T1/2为51.00分钟)(p < 0.001)。这种差异在后续评估中更为明显,尤其是在停止治疗后的第三周和第三个月测量时(p < 0.001)。所有受试者内效应检验均具有显著性(p < 0.001)。比较预处理和治疗后的闪烁扫描结果,99mTc-DTPA的平均T1/2值随着博来霉素剂量的增加而降低。

结论

我们得出结论,累积博来霉素剂量在256.5毫克时与肺上皮通透性增加有关。然而,这是否与临床毒性相关尚不确定,需要进行大规模、多中心的前瞻性研究。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验